Biogen (BIIB) EBIT Growth (1y) (2010 - 2026)
Biogen (BIIB) EBIT Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 7.43% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 31.43% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -111.70% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -2.34% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -9.81% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 32.30% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -520.13% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -15.58% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -76.09% |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | -563.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -563.67% |
| Mar 31, 2026 | 10.94% |
| Dec 31, 2025 | -88.87% |
| Sep 30, 2025 | 37.61% |
| Jun 30, 2025 | -8.97% |
| Mar 31, 2025 | -310.98% |
| Dec 31, 2024 | -328.84% |
| Sep 30, 2024 | 76.56% |
| Jun 30, 2024 | 32.32% |
| Mar 31, 2024 | 65.52% |
| Dec 31, 2023 | -70.99% |
| Sep 30, 2023 | -188.82% |
| Jun 30, 2023 | -85.31% |
| Mar 31, 2023 | -136.76% |
| Dec 31, 2022 | -25.09% |
| Sep 30, 2022 | 13.55% |
| Jun 30, 2022 | 61.73% |
| Mar 31, 2022 | -37.29% |
| Dec 31, 2021 | 277.59% |
| Sep 30, 2021 | -26.91% |